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BACKGROUND: Simultaneous inhibition of multiple components of the BRAF-MEK-ERK cascade (vertical inhibition) has become a
standard of care for treating BRAF-mutant melanoma. However, the molecular mechanism of how vertical inhibition synergistically
suppresses intracellular ERK activity, and consequently cell proliferation, are yet to be fully elucidated.
METHODS:We develop a mechanistic mathematical model that describes how the mutant BRAF inhibitor, dabrafenib, and the MEK
inhibitor, trametinib, affect BRAFV600E-MEK-ERK signalling. The model is based on a system of chemical reactions that describes
cascade signalling dynamics. Using mass action kinetics, the chemical reactions are re-expressed as ordinary differential equations
that are parameterised by in vitro data and solved numerically to obtain the temporal evolution of cascade component
concentrations.
RESULTS: The model provides a quantitative method to compute how dabrafenib and trametinib can be used in combination to
synergistically inhibit ERK activity in BRAFV600E-mutant melanoma cells. The model elucidates molecular mechanisms of vertical
inhibition of the BRAFV600E-MEK-ERK cascade and delineates how elevated BRAF concentrations generate drug resistance to
dabrafenib and trametinib. The computational simulations further suggest that elevated ATP levels could be a factor in drug
resistance to dabrafenib.
CONCLUSIONS: The model can be used to systematically motivate which dabrafenib–trametinib dose combinations, for treating
BRAFV600E-mutated melanoma, warrant experimental investigation.
British Journal of Cancer; https://doi.org/10.1038/s41416-021-01565-w
BACKGROUND
Mitogen-activated protein kinase (MAPK) pathways are present in
all eukaryotic cells and play a pivotal role in cellular processes
linked to proliferation, differentiation and apoptosis [1]. A general
MAPK pathway consists of a three-tiered cascade, with a MAPK
kinase kinase (MAPKKK) on the top tier, a MAPK kinase (MAPKK) on
the middle tier, and a MAPK on the bottom tier. Via sequential
kinase activation, signals can propagate through the MAPK
cascade in which the activated MAPKKK phosphorylates, and
thereby activates the MAPKK, which in turn phosphorylates, and
thereby activates the MAPK.
Several MAPKKK-MAPKK-MAPK cascades are present in eukar-
yotic cells, but in this study, we focus our attention on one such
cascade: the BRAF-MEK-ERK cascade. Mutations in this signalling
pathway have been identified as drivers for tumour development
and growth, and therefore this cascade is of particular interest in
the treatment of cancer. Upon activation, ERK can phosphorylate
numerous substrates in the cytoplasm and the nucleus, and
thereby regulate gene expression directly, by phosphorylating
transcription factors such as Elk, Ets and Myc, and indirectly, by
acting on substrates that in turn can modify transcription factors
[2]. These phosphorylation events, which are controlled by both
the amplitude and the duration of ERK activation, are crucial in
regulating intracellular processes, including cell proliferation.
In the early 2000s, it was established that BRAF oncogene
mutations occur in a majority of melanomas [3]. In melanomas
harbouring the BRAFV600E mutation, the most common BRAF
mutation [4], the BRAF kinase, is constitutively activated and thus
signalling through the BRAF-MEK-ERK cascade is hyperactivated
and always turned on, which can result in uncontrolled cell
proliferation [5, 6]. As a consequence, small-molecule inhibitors
that target the BRAF-MEK-ERK cascade have been developed, with
these inhibitors acting to inhibit the enzymatic activity of the
kinases in the cascade [7]. Such inhibitors ultimately suppress the
amount of activated ERK within a cell and, by extension, the cell’s
proliferative abilities. Such drugs have been shown to have
profound anti-tumour effects.
Vertical inhibition describes a treatment approach in which two
or more tiers in a cascade, such as the BRAF-MEK-ERK cascade, are
concurrently targeted [8]. In this paper, we specifically investigate
drug responses to monotherapies and combination therapies that
include the BRAF inhibitor dabrafenib (DBF) and the MEK inhibitor
trametinib (TMT). DBF is adenosine triphosphate (ATP)-competi-
tive inhibitor with specificity for the MAPKKK BRAFV600E, and TMT
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selectively inhibits the MAPKKs MEK1 and MEK2 [9]. TMT is an
allosteric inhibitor as it inhibits the enzymatic activity of MEK1 and
MEK2 by binding to a site that is distinct from the ATP-binding site
[10]. In 2011, the first selective inhibitor of mutated BRAF,
vemurafenib, was approved by the US Food and Drug Adminis-
tration for treating BRAF-mutant metastatic or unresectable
melanoma [11]. Thereafter, selective BRAF inhibitors replaced
the previously used chemotherapies in treating BRAFV600E and
BRAFV600K mutant melanoma in clinics, which significantly
improved patient survival [12]. However, drug resistance to
BRAF-inhibiting monotherapies commonly develops within
6–8 months of treatment [13–15].
In current treatment protocols, combined BRAF and MEK
inhibition is a standard of care for treating BRAFV600E-mutant
melanoma [13, 14, 16, 17]. Compared to BRAF-inhibiting mono-
therapies, such combination therapies have been shown to delay
the onset of drug resistance; in a clinical phase 3 trial, the median
progression-free survival was respectively reported to be 5.8 and
9.4 months for DBF mono treatments and DBF–TMT combination
treatments [14]. This, yet rapid, onset of drug resistance suggests
that current treatment regimens create a pressure that selects for
drug-resistant tumour subclones [15].
Multiple and diverse mechanisms have been empirically
identified as drivers for resistance to BRAF inhibitors, and one
important such mechanism is BRAFV600E amplification [18]. In a
multicenter meta-analysis study of clinically observed resistance
mechanisms in BRAFV600E-mutated melanoma, quantitative
genomic DNA PCR testing showed that BRAFV600E/K amplifica-
tion was present in 120 out of 132 patient biopsies [19]. Xue et al.
moreover experimentally showed that increased BRAFV600E
concentrations led to a growth advantage in A375 melanoma
cells in vitro, when the cells were treated with RAF, MEK or ERK
inhibitors [4]. Interestingly, in the absence of these drugs,
BRAFV600E amplification did not yield a growth advantage and
thus the authors concluded that the magnitude of BRAFV600E
amplification required for sustained BRAFV600E-MEK-ERK signal-
ling is drug-dependent. Xue et al. referred to this magnitude as
the fitness threshold. As part of their study, the authors further
showed, using patient-derived xenografts, that an increased
fitness threshold can be obtained via intermittent administration
of vertical MAPK inhibition.
Xue et al.’s fitness threshold model can be used to link drug
responses with the evolutionary selection of subclones within a
tumour, but does not explain why; on an intracellular level, an
increase in BRAFV600E concentration leads to a growth advantage
only in the presence of drugs. However, a recent study by Sale
et al. demonstrated that BRAFV600E-amplified cells can become
addicted to MEK inhibitors and that ERK1 or ERK2 activation post
drug withdrawal drives G1 cell-cycle arrest, senescence and cell
death [20]. This indicates that, during drug withdrawal,
BRAFV600E-amplified cells have a proliferative disadvantage
compared to non-BRAFV600E-amplified cells.
In order to further shed light on the effects of vertical inhibition
of the BRAFV600E-MEK-ERK cascade at a molecular level, we here
develop a mathematical model that mechanistically captures
cascade dynamics in the presence of DBF and TMT. Huang and
Ferrell developed the first mathematical model of a general MAPK
pathway [21], consisting of a three-tiered cascade in which double
phosphorylation of the MAPKKK, MAPKK and MAPK substrates is
required for activation. Using mass action kinetics, Huang and
Ferrell formulated the MAPK cascade in terms of a system of
ordinary differential equations (ODEs), which they solved numeri-
cally to simulate signalling dynamics within the cascade. Notably,
the authors showed that the structure of the MAPK cascade yields
ultra-sensitive signalling dynamics. In this study, we modify Huang
and Ferrell’s model to capture cellular signalling dynamics in a
specific MAPK pathway: the BRAF-MEK-ERK cascade in BRAFV600E-
mutant melanoma. As an extension to Huang and Ferrell’s model,
we introduce ATP-dependent substrate phosphorylation and
molecular drug actions of DBF and TMT.
METHODS
We develop a mathematical model that simulates the temporal BRAF-MEK-
ERK signalling dynamics in BRAFV600E-mutant melanoma. In order to do
this, we first map out the structure of the BRAF-MEK-ERK cascade and
identify the drug actions of DBF and TMT that, respectively, inhibit
enzymatic BRAF and MEK activity. From the cascade structure and drug
actions, we formulate a system of chemical reactions that captures
intracellular signalling dynamics. Using mass action kinetics, the system of
chemical reactions is thereafter re-formulated as a system of ODEs, which
are solved numerically in order to simulate the temporal evolution of
signalling molecule concentrations. A model output of particular
importance is the concentration of activated ERK over time, as the
ultimate goal of vertical inhibition of the BRAFV600E-MEK-ERK pathway is
to suppress cells’ activated ERK levels and, by extension, their proliferative
abilities. All model parameters (i.e. kinetic constants and total intracellular
protein concentrations) are obtained from data available in the literature
[21–29].
The BRAF-MEK-ERK cascade
We modify Huang and Ferrel’s cascade model [21] to specifically capture
the signalling dynamics of the BRAF-MEK-ERK cascade in BRAFV600E-






















Fig. 1 Cascade models. a The three-tiered general MAPKKK-MAPKK-MAPK cascade of Huang and Ferrell [21]. The star (*) denotes activated
MAPKKK, and E1 and E2 are unspecified enzymes that, respectively, activate and inactivate MAPKKK. The prefixes p and pp denote singly and
doubly phosphorylated proteins, and phosph1 and phosph2 are phosphatases that dephosphorylate MAPKK and MAPK, respectively. b Our
modified BRAF-MEK-ERK cascade in BRAFV600E-mutant melanoma, in which a specific MAPKKK (BRAF), MAPKK (MEK) and MAPK (ERK) are
considered. BRAF is constitutively activated, and therefore the top cascade tier is reduced to a single node, activated BRAF. The modified
cascade incorporates ATP-dependent substrate phosphorylation at the sites shown. Differences in the cascade structure between Huang and
Ferrell’s original model, and our model, are marked in red in (b).
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MAPK cascades and our problem-specific cascade are, respectively,
illustrated in Fig. 1a, b. Here, and throughout this work, singly and
doubly phosphorylated proteins are, respectively, denoted by the
prefixes p and pp. Note that double phosphorylation is required
for substrate activation and that phosphatases (phosphs) depho-
sphorylate singly and doubly phosphorylated MAPKK/MEK and
MAPK/ERK (Fig. 1). In our model, BRAF phosphorylates MEK and
once MEK has been doubly phosphorylated, it in turn phosphor-
ylates ERK, which becomes activated when doubly phosphory-
lated. As BRAF is constitutively activated in BRAFV600E-mutant
melanoma [6], we have reduced the top tier in our modified
cascade to contain only activated BRAF (Fig. 1b). Since the model
developed in this study will include the drug actions of DBF, which
is an ATP-competitive inhibitor, and TMT, which is an allosteric
ATP inhibitor, we extend Huang and Ferrell’s model to include
ATP-dependent substrate phosphorylation. Thus, in our model,
when a substrate and an ATP molecule bind to an enzyme (in the
absence of drugs), the ATP molecule donates a phosphate group
to the substrate, and the ATP converts to adenosine dipho-
sphate (ADP) after the metabolic process (Fig. 1b).
BRAF and MEK inhibitors
We model the pharmacodynamic actions of the two drugs DBF and TMT.
DBF is a potent and selective BRAF inhibitor, which is ATP-competitive [30].
As illustrated schematically in Fig. 2 (top), DBF can thus bind to the ATP site
of a BRAF molecule, and thereby inhibit BRAF-ATP reactions and the
downstream phosphorylation of MEK and pMEK. TMT is classified as an
allosteric MEK1/2 inhibitor, as it binds to a binding site that is distinct from,
but adjacent to, the ATP-binding site on the MEK molecule [31]. This is
illustrated schematically in Fig. 2 (bottom). MEK-bound TMT prevents MEK
from phosphorylating the substrates ERK and pERK.
The system of reactions
By combining the cascade illustrated in Fig. 1b, with the drug actions that
are schematically summarised in Fig. 2, we formulate a system of chemical
reactions that describes the signalling dynamics in the BRAFV600E-MEK-
ERK cascade subjected to drugs. This results in a system of 36 chemical
reactions (R.1–R.36) that are outlined in Fig. 3, where the order of the
binding events is considered.
The system of ordinary differential equations
We use the law of mass action to re-express the system of reactions
(R.1–R.36) as a system of ODEs. In the system of ODEs, the dependent
variables are the concentrations of the signalling molecules that occur in
(R.1–R.36), and the independent variable is time. In short, the law of mass
action says that the rate of a chemical reaction is proportional to the
product of the masses of the reactants. Thus, the first reaction, R.1, which
includes the molecules BRAF, ATP and BRAF·ATP, yields the following
contributions to the system of ODEs:
d BRAF½ 
dt
¼ a1 BRAF½  ATP½  þ d1 BRAF  ATP½ ;
d ATP½ 
dt
¼ a1 BRAF½  ATP½  þ d1 BRAF  ATP½ ;
d BRAF  ATP½ 
dt
¼ þa1 BRAF½  ATP½   d1 BRAF  ATP½ ;
where concentrations are denoted by square brackets surrounding the
signalling molecule of interest, and t denotes time. Note that the right-
hand sides of the above equations are subsequently extended to include
more equations derived from other reactions in the system of reactions
outlined in Fig. 3. The full system of ODEs (O.1–O.36) is available in the
Supplementary Material (SM1). In this work, we combine (O.1–O.36) with
a set of system conservation laws (C.1–C.7 in SM1) to formulate a system
of differential-algebraic equations that we solve numerically to obtain
the temporal evolution of the system molecule concentrations. The
conservation laws ensure that the total concentrations of the kinases
BRAF, MEK and ERK (in free, bound, non-phosphorylated, singly
phosphorylated and doubly phosphorylated form), phosphatases (in
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Fig. 2 Schematics of the mathematical models that describe dabrafenib (DBF) and trametinib (TMT) drug actions. (Top) aWe consider two
BRAF binding sites: one that can bind MEK and one that can bind ATP or dabrafenib. BRAF-bound ATP is necessary for the phosphorylation of
MEK. b If ATP and MEK are bound to BRAF, then MEK is phosphorylated to the singly phosphorylated form pMEK. c If ATP and pMEK are bound
to BRAF, then pMEK is phosphorylated to the doubly phosphorylated form ppMEK. d, e BRAF-bound dabrafenib prevents ATP from binding to
BRAF, and thereby inhibits the phosphorylation of the substrates MEK and pMEK. (Bottom) a We consider three MEK-binding sites: one that
can bind ERK, one that can bind ATP and one that can bind trametinib. ppMEK-bound ATP is necessary for the phosphorylation of ERK. b If ERK
and ATP, but not TMT, are bound to ppMEK, then ERK is phosphorylated to the singly phosphorylated form pERK. c If pERK and ATP, but not
TMT, are bound to ppMEK, then pERK is phosphorylated to the doubly phosphorylated form ppERK. d, e If TMT is bound to ppMEK, the
phosphorylation of the substrates ERK and pERK is inhibited.
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Model implementation
We implement and solve the system of ODEs (O.1–O.36), with conservation
laws (C.1–C.7) in silico, in order to simulate the signalling dynamics in the
BRAF-MEK-ERK cascade. The in silico model, which is developed using the
programing language and computing environment MATLAB, is available on
the code hosting platform GitHub. Instructions on how to access, run and
modify the code are available in the Supplementary Material (SM2, Fig. SF1).
Model parameters
The system of reactions (R.1–R.36) includes eight forward rate constants a1,
a2, …, a8, eight reverse rate constants d1, d2, …, d8, and four catalytic rate
constants k1,2, k3, k5,6, k7. The values of these constants are listed in Table
ST1 in the Supplementary Material (SM3). Huang and Ferrell [21] argued
that, when computing steady-state enzyme levels, it is not the individual
rate constants, but rather the Michaelis constants, Kmi= (di+ ki)/ai, that are
important. We, therefore, set all forward rate constants ai to be the same so
that aj= a1 for all j= 2, 3, ..., 8. We then use data available in the literature
to set the parameter values for a1, the eight reverse rate constants and the
four catalytic rate constants, as is outlined in the Supplementary Material
(SM4). The model initial condition, i.e. a vector that includes the molecule
concentrations at the start of the simulation, is also obtained from data in
the literature [21, 28]. Initial cascade component concentrations are listed
in Table ST2 in the Supplementary Material (SM3).
Results
Using the in silico model that we have developed, the temporal evolution
of the concentration of all signalling components appearing in the system
of reactions (R.1–R.36) are computed. In this study, our main model output
of interest is activated ERK. For ease of presentation, we define a measure
activated ERK, as a time-dependent fraction,
activated ERK ¼ ½ppERKðtÞ
ERKtot
;
where ERKtot denotes the total amount of ERK in the system, such that
ERKtot= [ERK](0), as listed in Table ST2 in the Supplementary Material (SM3).
Monotherapy results
We initially investigate how activated ERK levels within a cell change in
response to DBF or TMT monotherapy. The temporal evolution of activated
ERK in response to these monotherapies are shown in Fig. 4a and b,
respectively. Activated ERK levels at specific time points are plotted over
intracellular concentrations of BRAF (left panel) and ATP (right panel) for
different doses of DBF (Fig. 4c) and TMT (Fig. 4d).
The simulation data show that the modelled DBF treatment responses
are highly dynamic in time, and are dependent on both intracellular BRAF
and ATP concentrations (Fig. 4a, c). These data also suggest that increased
concentrations of BRAF and ATP make the cells less sensitive to DBF.
Further, these data show that the activated ERK levels eventually reach the
same steady-state value for several DBF–BRAF–ATP concentration combi-
nations (see also Supplementary Material SM5, Fig. SF2). In order for a cell
to progress from the G1 to the S phase of the cell cycle, sustained ERK
activity throughout the G1 phase is required, where ERK downregulates
several anti-proliferative genes until the S-phase entry [32, 33]. This
suggests that, if ERK activity can be suppressed for the duration of the G1
cell-cycle phase, further cell-cycle progression, and thus cell proliferation,
can be inhibited.
In response to different TMT doses, activated ERK levels reach distinct
steady-state levels (Fig. 4b). Moreover, TMT treatment responses at time
(R.1) BRAF + ATP (R.19) ppMEK·ATP + pERK
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(R.21) ppMEK·pERK + ATP
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Fig. 3 System of reactions (R.1–R.36) describing the signalling dynamics in the BRAFV600E-MEK-ERK cascade subjected to the drugs
dabrafenib (DBF) and trametinib (TMT). The dot notation (·) denotes complexes of two or more molecules. Reactions involving dabrafenib
and trametinib are, respectively, marked by a single (*) and double (**) stars and can be omitted when simulating the system in the absence of
these inhibitors.
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points after 8 h are only sensitive to BRAF variations for low BRAF
concentrations (under 3 nM) and the efficacy of TMT treatments is not
sensitive to variations in ATP within the range of concentrations tested
(Fig. 4d).
Combination therapy results
We next evaluate the effect of combination therapies involving DBF and
TMT on treatment outcome (Fig. 5). When DBF concentrations are zero (i.e.
for TMT monotherapies) the activated ERK levels do not vary between 8
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Fig. 4 Plots showing activated ERK levels (as defined in Eq. 2) in response to monotherapies of dabrafenib or trametinib, where the drug
doses are indicated in the legend at the bottom of the figure. a The temporal evolution of activated ERK. Results are shown for different
intracellular concentrations of BRAF, ATP and dabrafenib (DBF). b The temporal evolution of activated ERK. Results are shown for different
intracellular concentrations of BRAF and trametinib (TMT). c, d Activated ERK levels are plotted over intercellular BRAF concentrations, where
ATP concentrations are fixed at the baseline value 1mM (left). Activated ERK levels plotted over intercellular ATP concentrations, where BRAF
concentrations are fixed at the baseline value 3 nM (right). Results at 8, 16 and 24 h are shown in dashed, dotted and solid lines, respectively,
for different doses of dabrafenib (c) and trametinib (d).
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and 24 h. However, when TMT concentrations are zero (i.e. for DBF
monotherapies), the activated ERK levels do vary between 8 and 24 h and,
as a consequence, so does DBF–TMT combination therapies (Fig. 5a–c).
In order to determine whether there is DBF–TMT synergism, we included
an isobole that connects the two monotherapy doses that yield an
activated ERK level of 0.5 (Fig. 5a). Since drug combinations below this line
can achieve activated ERK levels lower than 0.5, the drug combination is
categorised as synergistic [34].
In Fig. 5b, c, the BRAF and ATP levels have been increased from the
baseline parameter values. By comparing Fig. 5a with Fig. 5b, c, we can see
that activated ERK levels increase with increased BRAF and ATP levels. Our
mathematical model, therefore, predicts that increased intracellular BRAF
and ATP concentrations will generate resistance to DBF–TMT combination
therapies.
The influence of BRAF concentration on DBF–TMT efficacy is also reflected
in Fig. 5d. We see from these results the minimum BRAF concentration that is
required to achieve an activated ERK level of 0.5 at 24 h (when ATP is fixed at
the baseline value 1mM). Similarly, the minimum ATP concentration that is
required to achieve an activated ERK level of 0.5 at 24 h (when BRAF is fixed
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Fig. 5 Heatmaps showing treatment responses to dabrafenib–trametinib (DBF–TMT) combination therapies. For each square in the
heatmap, the horizontal axis of the intersection denotes the dabrafenib dose, and the vertical axis denotes the trametinib dose. a–c The
fraction of activated ERK (as defined in Eq. 2) at 8, 16 and 24 h are shown in the left, middle and right columns, respectively. BRAF and ATP
concentrations vary between (a), (b) and (c). The right panel in (a) includes an isobole that connects the two monotherapy drug doses that
yield an activated ERK level of 0.5 with a straight red line. Drug combinations below this line that yield activated ERK levels of 0.5 or less are
categorised as synergistic. d, e The minimum BRAF (d) and ATP (e) concentrations that are required to yield an activated ERK level over 0.5 at
24 h are shown. In d, the ATP concentration is fixed at 1mM. In (e), the BRAF concentration is fixed at 3 nM. For DBF–TMT combination doses
where the activated ERK does not surpass 0.5 for BRAF concentrations under 20 nM, the squares in the heatmap in (d) are not coloured.
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DISCUSSION
Although targeted anticancer drugs can generate patient
responses in tumours previously intractable to treatment, there
remain major issues in their clinical use. In particular, tumour
regrowth may occur due to a rapid onset of drug resistance. A
number of mechanisms of drug resistance have been described
for example for drugs targeted at mutant BRAF in the MAPK
pathway. Many of these involve the modulation of components of
the pathway, e.g. by mutation or gene amplification. This results in
the sustained activation of ERK in the presence of drugs. As a
consequence, drugs targeted at multiple components of the same
pathway have been used in combination, e.g. BRAF and MEK
inhibitors. Although this has resulted in some patient benefit, this
has not resolved the problem and major challenges still remain.
There is currently great interest in further developing the
complexity of combination treatments. In the case of the BRAF
pathway, e.g. by the addition of an inhibitor of ERK [4].
Increasing treatment complexity, however, raises some major
pharmacological challenges, including which drugs to use in
combination and what doses to use in order to keep toxicity at an
acceptable level. At clinically administered doses, BRAF and MEK
inhibitors lead to a number of side effects that are generally
categorised to be non-life-threatening and safe when adequately
monitored [35, 36]. Common adverse events induced by DBF
include hyperkeratosis, headache, arthralgia and pyrexia, whilst
TMT commonly induces rash, diarrhoea, fatigue, peripheral
oedema and acneiform dermatitis. DBF–TMT combination regi-
mens have not been reported to yield any new adverse events.
However, fever, chills, fatigue, diarrhoea, hypertension and
vomiting are more frequently observed in response to combina-
tion therapies than in response to the corresponding mono-
therapies. On the contrary, cutaneous adverse events, such as
squamous cell carcinoma and skin papilloma, occur less frequently
in response to DBF–TMT combination therapies than in response
to DBF monotherapies [35].
The vast number of drug combinations and dosing regimens
that could be evaluated makes it impossible to test all these either
in the laboratory or in the clinic. Informative in silico pharmaco-
logical models are therefore needed.
Several research groups have analysed and modified Huang
and Ferrell’s MAPK cascade model since it was presented in 1996
[21], as is summarised in a review by Orton et al. [2]. Mathematical
analysis and computational simulation of the MAPK cascade
model has explained how the dual phosphorylation and depho-
sphorylation events mechanistically give rise to the ultrasensitivity
of ERK activation [37, 38] and bistability [39]. Integrated in vitro-
mathematical work has further demonstrated switch-like (on or
off) ERK activity in single cells in Xenopus oocytes subjected to
progesterone [40]. Moreover, MAPK cascade models of various
complexities have been presented and investigated in the
literature, where these have included, e.g. the internalisation
and downstream signalling activity of the epidermal growth factor
receptor [41, 42].
To our knowledge, the mathematical model presented in this
paper is the first MAPK cascade model to (i) specifically capture
signalling dynamics in the BRAFV600E-MEK-ERK cascade, (ii)
explicitly include ATP-dependent substrate phosphorylation, and
(iii) include mechanistic drug actions of DBF and TMT, where the
model parameters involved in (i–iii) are obtained from published
in vitro data.
In this paper, we have developed a mathematical model that
captures signalling dynamics in the BRAFV600E-MEK-ERK cascade,
in response to DBF and TMT treatments. Our in silico model can be
used to quantify the temporal evolution of system molecule
concentrations and, as a consequence, ERK activity. The model
predicts that increased cellular BRAF and ATP concentrations will
result in reduced sensitivity to DBF–TMT combination therapies.
The prediction that ATP levels may influence drug sensitivity
introduces an important variable to take into consideration when
evaluating treatment responses. Intratumoural heterogeneity
generated by both spatio-temporal factors (such as varying ATP
levels within a tumour) and phenotypic factors (such as
differences in BRAF amplification between cells) has been
recognised to fuel drug resistance and complicate the design of
treatment strategies [43, 44]. Our finding that increased BRAF
concentration is associated with drug resistance is furthermore
consistent with experimental data [4].
Whilst simulation of the ERK activation level at different
concentrations of DBF and 3 nM BRAF closely followed that
observed in patients [45], an increase of the BRAF level to 10 nM in
our model, similar to that found in drug-resistant patient-derived
xenografts [4], predicted marked resistance of the ERK activation
to treatment with DBF. This is shown in Fig. 6, where simulation
results are superimposed over clinical data obtained from a study
in which phosphorylated ERK levels were measured in BRAFV600-
positive melanoma biopsy samples before, and 5 days after, DBF
monotherapy administration where doses between 70 and 200
mg were administered twice daily [45]. The recommended DBF
dose for unresectable or metastatic BRAFV600E-positive mela-
noma is 150 mg twice daily [6].
In order to investigate three-drug vertical inhibition of the
BRAF-MEK-ERK pathway in BRAFV600E-mutant melanoma, the
model could directly be extended to include the effects of an ERK
inhibitor. As a further development of the modelling, one could
study the effects of DBF–TMT treatment scheduling in a multi-
cellular system using a multi-scale, agent-based model (ABM)
[46, 47]. In order to implement the pathway model into an ABM,
the relationship between ERK activity and cell-cycle progression/
inhibition and cell death needs to be established [32, 33, 48]. This
is one aim of our future modelling studies. ABMs are naturally able
to incorporate spatio-temporal variations in intracellular BRAF and
ATP concentrations amongst cells, where these variations are
derived from both genetic, phenotypic and environmental factors
[49, 50]. ABMs can thus be used to simulate how drug-resistant
tumour subclones (e.g. melanoma cells with elevated BRAF levels)
and drug-sensitive tumour subclones evolve in time and space in
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Fig. 6 Plots showing changes in phosphorylated ERK ([pERK]+
[ppERK]) from the baseline (no drug) level. Simulation results at
8 h, when the ATP concentration is fixed at 1 mM, are shown for
BRAF concentrations of 3 and 10 nM. The circles show patient data
from a clinical study by Falchook et al. [45], where dabrafenib was
administered twice daily at doses between 70 and 200mg.
Dabrafenib concentrations are shown in µM (used in other
simulations results in this article) along the top axis and ng/mL
(the effective concentration measured in the clinical study) along
the bottom axis. To convert between µM and ng/mL, we have used
that the molecular weight of dabrafenib is 519.6 g/mol [53].
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treatment schedules. As an alternative future model extension to
spatially explicit and stochastic ABMs, the model developed in the
study can be integrated within a deterministic, age-structured cell
population model in which the cell-cycle dynamics is dependent
on ERK activity.
Thus, via a data-driven and bottom-up modelling approach [51],
the in silico model developed in this study can be built upon to
simulate how BRAF-MEK-ERK inhibition affects not only intracel-
lular ERK activity but also the progression of drug resistance in
melanoma tumours. Previous experimental work has shown that
drug combinations, drug doses and treatment schedules all
impact the evolution of drug-resistant tumour subclones in
melanoma when the tumours are subjected to inhibitors that
target the BRAF-MEK-ERK pathway [4, 52].
The predictive power of quantitative in silico models, such as
that described here, is dependent on the accuracy of the kinetic
constants for the different components of the signalling cascade
as well as on the relative concentrations of the individual enzymes
in the cascade. We would suggest that in the light of their key
importance further studies are needed to validate the accuracy of
the kinetic constants used. Indeed, translating such models to the
treatment of individual cancer patients in the future may require
the concentration and activity of the signalling components to be
measured on an individual basis.
The mathematical model described in this study provides a
method to quantitatively assess how vertical DFB–TMT inhibition
suppresses ERK activity. We note that the modelling approach
outlined in this paper can also be applied to other signalling
cascades targeted in cancer treatment. Mathematical oncology
models that are developed alongside experiments can be used to
systematically motivate which drug combinations, drug doses and
treatment schedules warrant experimental investigation [47].
CODE AVAILABILITY
Simulation code is available on the code hosting platform GitHub. Instructions on
how to access, run and modify the code are available in the Supplementary
Material (SM2).
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